Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 23;127(10):1865–1875. doi: 10.1038/s41416-022-01953-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — A high 6 Gene Proliferation Score (6GPS) associated with shorter disease-specific survival (a METABRIC discovery cohort; Q1-Q4 representing quartiles 1–4). Recurrence-free breast cancer survival according to 6GPS in the GSE25066 cohort (b), and in the cohorts from the online “KM plotter” database (www.kmplot.com); c). When adjusting for traditional prognostic variables, the 6GPS demonstrated independent association with shorter disease-specific survival (d; Cox multivariate analysis), also when adding molecular subtypes to the analysis (e). Dotted lines represent a hazard ratio (HR) of 1.0, and error bars represent 95% CI. A high 6GPS was also significantly associated with shorter survival in Luminal A tumours (METABRIC discovery and “KM plotter” cohorts; f, g). High expression of 6GPS associated with shorter disease-specific survival in luminal, lymph node negative, Oncotype Dx intermediate score cases (h METABRIC validation cohort).